An oncology treatment pioneered by ZYMEDI that overcomes current limitations
Despite immense efforts to win the war against cancer for the last several decades, cancer continues to be one of most life-threatening diseases.
Aminoacyl-tRNA synthetases (ARSs) are an unrealized target in oncology treatment because cancer cells abuse ARSs to fill up higher demand for protein synthesis and to make a more cancer-friendly environment.
Although KRAS-targeted therapies have recently come to market, they have a narrow mutational focus and serve only a limited patient population.
A pan-KRAS inhibitor targeting AIMP2-DX2 for KRAS-mutated cancers
Our unique ARS target platform can help develop drugs to fill the missing gap in current oncology therapy.
With multiple promising candidates in our oncology pipeline, the lead candidate is a pan-KRAS inhibitor targeting AIMP2-DX2 for KRAS-mutated cancers, including colon, lung, and pancreatic.
Although KRAS has traditionally been difficult to target, this
breakthrough therapeutic can block the interaction between KRAS and AIMP2-DX2, leading to degradation of KRAS and reduced level of KRAS in cancer.
A unique oncology target platform
ARSs are not only essential enzymes for protein synthesis, but also multifunctional system controllers for homeostasis. Cancer cells provoke ARSs to fill up higher demand for protein synthesis or to create a more cancer-friendly environment.
ZYMEDI focuses on the previously overlooked significance of ARSs in cancer. We have established a unique oncology platform for the development of first-in-class drugs that can save the lives of cancer patients who get little therapeutic benefit from currently available drugs.
